Read the full release \u2192<\/a><\/p>\nNews provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamabFull data expected in fourth quarter of 2026LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and\u2026<\/p>\n","protected":false},"author":14,"featured_media":3112,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-3111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\n
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamabFull data expected in fourth quarter of 2026LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T11:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\",\"datePublished\":\"2026-06-30T11:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"},\"wordCount\":58,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\",\"name\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png\",\"datePublished\":\"2026-06-30T11:15:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte","og_description":"100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamabFull data expected in fourth quarter of 2026LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-30T11:15:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial","datePublished":"2026-06-30T11:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"},"wordCount":58,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","name":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png","datePublished":"2026-06-30T11:15:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-ai.png","width":1536,"height":1024,"caption":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/3111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=3111"}],"version-history":[{"count":0,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/3111\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/3112"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=3111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=3111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=3111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}